Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia
Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. J Urol. 2013 Jan 25. pii: S0022-5347(13)00097-9. doi: 10.1016/j.juro.2013.01.061. [Epub ahead of print]


Social & Scientific Systems, Inc., Silver Spring, MD. Electronic address: cfwu@s-3.com.



To examine the effects of doxazosin, finasteride and combination therapy among men with benign prostatic hyperplasia (BPH) on quality of life (QoL) assessed by a general (the Medical Outcomes Study Short-Form-36 [MOS-SF-36]) and two disease-specific instruments (the BPH Impact Index [BII] and the International Prostate Symptom Score [IPSS]-QoL) over 4 years.


The Medical Therapy of Prostatic Symptoms (MTOPS) Study was a multi-center, randomized, double-blind, placebo-controlled clinical trial with a primary outcome of time-to-BPH progression. Change in QoL was a secondary outcome. A total of 2,872 men enrolled in the MTOPS Study who had three baseline QoL measures and at least one follow-up measure by any of the QoL instruments were analyzed.


Compared with men assigned to placebo, men assigned to doxazosin and combination experienced a statistically significant improvement in the BII at year 4. Men assigned to each of the drug groups also experienced a significant improvement in the IPSS-QoL compared with those assigned to placebo. Considering longitudinal changes over 4 years, a significant improvement in BII and IPSS-QoL scores was observed in men assigned to the drug groups compared with those assigned to placebo. However, there were no significant differences for the MOS-SF-36 subscales and summary scores when drug groups were compared with the placebo group.


QoL of men treated with doxazosin, finasteride, and the drugs combined generally improved when assessed with the BII and the IPSS-QoL compared with those treated with placebo. QoL did not show improvement when measured by the MOS-SF-36.